TABLE 1.
Ongoing interventional clinical trials targeting AP in kidney diseases
| ID number | Acronym or other ID number | Targeted protein | Status | Conditions | Interventions | Phase | Number of patients | Age |
|---|---|---|---|---|---|---|---|---|
| NCT04859608 | EspacECU | C5 | Recruiting | aHUS | Eculizumab | 4 | 80 | 18 y and older |
| NCT04958265 | COMMUTE‐p | C5 | Recruiting | aHUS | Crovalimab | 3 | 35 | 28 d to 17 y |
| NCT04861259 | COMMUTE‐a | C5 | Recruiting | aHUS | Crovalimab | 3 | 90 | 12 y and older |
| NCT04889430 | APPELHUS | Factor B | Recruiting | aHUS | Iptacopan | 3 | 50 | 18 y and older |
| NCT03131219 | ALXN1210‐aHUS‐312 | C5 | Active, not recruiting | aHUS | Ravulizumab | 3 | 31 | up to 17 y |
| NCT02949128 | ALXN1210‐aHUS‐311 | C5 | Active, not recruiting | aHUS | Ravulizumab | 3 | 58 | 12 y and older |
| NCT05067127 | VALIANT | C3 | Recruiting | C3G, IC‐MPGN, post‐Tx C3G or IC‐MPGN recurrence | Pegcetacoplan | 3 | 90 | 12 y and older |
| NCT04572854 | NOBLE | C3 | Recruiting | post‐Tx C3G or IC‐MPGN recurrence | Pegcetacoplan | 2 | 12 | 18 y and older |
| NCT03955445 |
LNP023 Extension study |
Factor B | Recruiting | C3G, post‐Tx C3G recurrence | Iptacopan | 2 | 95 | 18 y and older |
| NCT04817618 | APPEAR‐C3G | Factor B | Recruiting | C3G | Iptacopan | 3 | 68 | 18–60 years |
| NCT03453619 | APL2‐201 | C3 | Active, not recruiting | C3G, IgAN, LN, MN | Pegcetacoplan | 2 | 21 | 18 y and older |
| NCT05162066 | RENEW | Factor D | Active, not recruiting | C3G, IgAN, MN | BCX9930 | 2 | 42 | 18 y and older |
| NCT05097989 | ALXN2050‐NEPH‐201 | Factor D | Recruiting | IgAN, LN | ALXN2050 | 2 | 126 | 18–75 years |
| NCT04154787 | CLNP023D12201 | Factor B | Recruiting | MN | Iptacopan or Rituximab | 2 | 52 | 18 y and older |
| NCT03841448 | ALN‐CC5‐005 | C5 | Active, not recruiting | IgAN | Cemdisiran | 2 | 31 | 18–65 years |
| NCT04578834 | APPLAUSE‐IgAN | Factor B | Recruiting | IgAN | Iptacopan | 3 | 450 | 18 y and older |
| NCT04557462 | LNP023 Rollover Extension Program (REP) | Factor B | Recruiting | IgAN | Iptacopan | 3 | 410 | 18 y and older |
| NCT04564339 | SANCTUARY | C5 | Recruiting | IgAN, LN | Ravulizumab | 2 | 120 | 18–75 years |
| NCT05268289 | CLNP023K12201 | Factor B | Recruiting | LN | Iptacopan | 2 | 240 | 18 y and older |
Note: Retrieved from ClinicalTrials.gov database 1 September, 2022 https://clinicaltrials.gov/ct2/home
Strategy: aHUS OR Glomerulonephritis; Recruiting/Active, not recruiting; Interventional Studies; Phase 2, 3, 4; selected for drugs targeting alternative or terminal pathway of complement.
Abbreviations: aHUS, atypical hemolytic uremic syndrome; AP, alternative pathway of complement; C3G, C3 glomerulopathy; IC‐MPGN, immune complex‐associated membranoproliferative glomerulonephritis; IgAN, IgA nephropathy; LN, Lupus nephritis; MN, membranous nephropathy; Tx, transplant.